Management of pediatric plaque psoriasis using biologics

Psoriasis is a chronic inflammatory disease with clinical manifestations of the skin that affect adults and children. In adults, biologics have revolutionized the treatment of moderate to severe plaque psoriasis where clear or almost clear is a tangible goal. Research on biologics has recently been...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Academy of Dermatology 2020-01, Vol.82 (1), p.213-221
Main Authors: Lansang, Perla, Bergman, James N., Fiorillo, Loretta, Joseph, Marissa, Lara-Corrales, Irene, Marcoux, Danielle, McCuaig, Catherine, Pope, Elena, Prajapati, Vimal H., Li, Sue Z.J., Landells, Ian
Format: Article
Language:English
Subjects:
adolescent
biologics
children
monitoring
pediatric
psoriasis
systemic therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Psoriasis is a chronic inflammatory disease with clinical manifestations of the skin that affect adults and children. In adults, biologics have revolutionized the treatment of moderate to severe plaque psoriasis where clear or almost clear is a tangible goal. Research on biologics has recently been extended to children. The introduction of these new therapeutic options has outpaced the limited guidelines in this population. To provide a review of current data on biologics, with a proposal for a clinically relevant treatment algorithm on the management of moderate to severe plaque psoriasis in the pediatric population. A Canadian panel with expertise in psoriasis, pediatric dermatology, and experience with consensus recommendation processes was selected to review the current landscape of pediatric psoriasis and clinical data on biologics plus identify special considerations for baseline workup and monitoring. Recommendations were reviewed and edited by each expert in an iterative process. A treatment algorithm for moderate to severe plaque psoriasis in pediatric patients is presented, incorporating approved biologics. Guidance on baseline screening and ongoing monitoring is also provided. Ultimately, treatment choice depends on the patient and his or her caregiver, with consideration of comorbidities, impact on quality of life, and relevant safety aspects.
ISSN:0190-9622
1097-6787
DOI:10.1016/j.jaad.2019.05.056